Abstracts Banner

Important Dates

September 17, 2019
Online abstract submission site opens
January, 2020
Deadline for Platform Presenter Documents to be Complete
November 5, 2019, 11:59 pm PST
Deadline to submit an abstract(s) Deadline to submit for an abstract award
February 11, 2020
Poster Withdrawal Deadline
Advance Registration Deadline
December 2, 2019
Acceptance/Rejection Notification Presenter Assignments
March 2020
Platform Presentation Slide Upload Deadline
December 11, 2019
Early Bird Registration Deadline
March 17 - 21, 2020
See you in San Antonio!

Continue to receive communications about the ACMG Annual Clinical Genetics meetings. Update your Privacy Preferences here

During submission, submitters must choose one of the three submission types in which they would like the abstract considered for acceptance. The choice must be made at the time of submission and cannot be changed after the review committee has reached its decision.

Submission options:

1. Poster Presentation Only
• Abstracts submitted for poster presentation only will NOT be considered for a platform presentation, regardless of score.

2. Platform Presentation Only
• Abstracts submitted for platform presentation only will NOT be considered for a poster, regardless of score.

3. Platform or Poster Presentation
• Abstract will be considered as a platform presentation or as a poster, depending on score.
• The submitter serves as point of contact for all correspondence regarding the abstract.
• The presenting author must be one of the co-authors listed on the submitted abstract. The presenting author must be confirmed prior to abstract submission.
• The presenting author is responsible for the following:
    - Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to get approval from all authors will result in rejection of the abstract.
    - Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ACMG.
• An individual may be first author (i.e., presenting author) of more than one abstract. If the first author should have multiple accepted posters and has a conflict with the poster presentation schedule, then it is acceptable to designate one of the co- authors to present one of the posters.
Each abstract author agrees and certifies that he or she:
- has read all of the rules and agrees to be bound by them,
- is responsible for submission of the abstract in accordance with the rules, and
- waives any and all claims against ACMG and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.
• The abstract must address scientific questions, detail clinical observations, or contain primary scientific data.
• Authors assign copyright of the abstract to ACMG upon submission, unless one of the authors is a U.S. Federal employee (in such case, ACMG does not hold copyright). This means that the identical abstract may not be republished or submitted to another meeting.
• All research and studies reported in submitted abstracts that involve human and animal subjects must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.
• Interim analysis of a prospective randomized clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, use the Interim Analysis of a Clinical Trial section of the abstract form to explain the details of your study. The reviewers will have this information available during their evaluation.
• No revisions can be made after the abstract submission deadline (November 5, 2019).
• The presentation at the annual meeting must reflect the submitted abstract. In particular, the abstract title, authorship, and scientific content of the presentation at the annual meeting must match the submitted abstract.
• Abstracts should be written in clear and concise English, so that reviewers can focus solely on the scientific merits of the submission. We encourage non-English-speaking authors to have their abstracts checked for grammar and spelling prior to submission.
• It is assumed that the presenting author will have adequate command of English to present and to respond to questions. If that is not the case, the authors should choose a poster as their preference.
• Abstracts can be submitted if:
- It is unpublished and original
- Accepted for publication but not yet published
- Encore presentations are allowed, only if material was previously presented at a non-genetics meeting within the last 6 – 12 months.
• After the submission deadline, all completed and eligible abstracts will be made available to the ACMG Abstract Reviewers for review and scoring, and final decisions will be made by the Abstract Reviewers in early December 2019.
• Abstracts will be evaluated and scored solely on their scientific merits.
• Incomplete abstracts will not be reviewed.
• The same study must not be submitted as multiple abstracts. Abstracts that are simply different versions of a single study will be rejected.
• Abstracts will be peer reviewed according to the subject categories. Authors must indicate during online submission the appropriate review category (one only). All category selections will be final. There will be NO re-classification of abstracts after the abstract submission site has been closed. Abstracts submitted in the wrong category are scored in that category and usually will receive a poor score.
• All abstracts submitted will be considered eligible for one presentation format as explained above: either a platform or a poster.
- Platform Presentations are formal platform presentations (15 minutes) that include a brief discussion. Of the abstracts selected, four of the highest rated will be featured in a special plenary session.
- Poster Sessions allow the viewing of a poster illustration of the abstract. Authors are expected to post and remove posters at designated times and to be at their posters to answer questions during the time designated for poster presentations. Poster presentations are assigned as to presenting on Thursday or Friday, March 19th and 20th. This assignment will not be changed, and presenters are required to be at their posters during the designated time. Top rated abstracts selected for Poster Presentation will be highlighted at the meeting venue and in the ACMG Program.

Acceptance/Rejection Notification
• Notification regarding acceptance or rejection of abstracts will be sent to the presenting author in December 2, 2019 by email; consequently, an accurate email address is critical. If your abstract is accepted, the email will specify whether it is accepted as platform or poster presentation.
• To ensure that you can receive email correspondence from ACMG, please make sure that your email software can receive mail from the acmg.expoplanner.com and acmg.net domains. If after completing your submission you don't receive a confirmation email from the abstract system, you must contact your system administrator and make sure that both domains are added to your email address whitelist. Ask your IT department to allow email from ip4:
• The decision of the ACMG Program Committee regarding acceptance and presentation of abstracts is final.
• Once your abstract has been reviewed and accepted as a poster, they are assigned poster numbers at random. The poster number determines the date and time of your poster presentation. The numbering of posters cannot and will not be changed. Posters are to be put on the poster boards by 5:30 pm on Wednesday, March 18th and are to remain up throughout the meeting.
Poster Presentations ODD Numbers Thursday, March 19th, 2020 10:00am-11:30am
Poster Presentations EVEN Numbers Friday, March 20, 2020 10:30am-12:00pm
• Printed posters should be created in the following dimensions:
42” x 44” OR 44” x 44”
Financial Disclosure Policy
It is the policy of the American College of Medical Genetics and Genomics to plan and implement all of its educational activities in accordance with the ACCME Essentials and Areas and ACCME® Policies to ensure balance, independence, objectivity and scientific rigor. In accordance with the ACCME® Standards for Commercial Support, everyone (speakers, moderators, platform presenters, all authors, committee members, and staff) who is in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit™ is required to disclose all financial relationships with any commercial interests (see definition below) within the past 12 months that creates a real or apparent conflict of interest. Individuals who do not disclose are disqualified from participating in a CME activity.

This disclosure pertains to relationships with: pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services may be related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be resolved prior to the educational activity. Disclosure of off-label, experimental or investigational use of drugs or devices must also be made known to the audience. • By completing this section of the online abstract submission, you agree that you have read the ACMG Financial Disclosure Policy and that you understand and support its intent.
• This policy is not intended to prevent a presentation; it is merely intended to openly identify potential conflicts so that audience members may form their own judgments about the presentation with a full disclosure of the facts.

Platform Presenters Responsibility Regarding Financial Disclosure (ACCME Compliance)
Accreditation Rules
• The presenting author for a platform presentation will be contacted and must complete the online financial disclosure form and additional items pertaining to their presentation and participation.
• Employees of ACCME defined commercial interests may not present a platform presentation.
• The content of the information with which you are involved will promote quality in health care or advances in science and will not promote a specific proprietary or commercial interest. Content for this publication will be well-balanced and unbiased.

Accreditation Council for Continuing Medical Education (ACCME) Definition of Commercial Interests
A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
A diagnostic laboratory is not considered an ACCME-defined commercial interest if its business is limited to the provision of diagnostic services that provide clinical results or information to healthcare professionals for their treatment of patients.
Contact Information
• Your name, degree, institution, address, phone number, and email address must be provided. As the corresponding author, you will receive all future correspondence from ACMG.
• The submitting author should be the first author (presenter) of the abstract, unless otherwise noted during submission.

• Names of co-authors and institutions must be provided. Changes will not be made to the spelling of authors’ names after the submission deadline; please proof your co-authors’ names carefully.

Copyright Policy
• All authors must assign copyright of the abstract to ACMG, unless one of the authors is a U.S. Federal employee (in such case, ACMG does not hold copyright).

Abstract Title
• The abstract title should be brief and clearly indicate the nature of the abstract. You may use up to 20 words.
• The abstract title must be in title case. Capitalize all nouns, pronouns, adjectives, verbs, adverbs, and subordinate conjunctions (i.e., as, because, although). Except for the first word of the title, lowercase all articles, coordinate conjunctions (i.e., and, or, nor), and prepositions, regardless of length. Also, lowercase “to” when used as an infinitive.
• Additionally, keep letters lowercase if the lowercase letters have a specific meaning, such as aCGH or NIPT.
• Do not put a period at the end of the title.
•For example: Cancer Genetics: Translation of New Concepts to Clinical Care

Use of Product Names
• Non-proprietary (generic/scientific) names should be used and should be lowercase.
• If necessary, you may include a proprietary name in parentheses directly following the generic name after its first mention in the body of the abstract; the first letter of the name of a proprietary drug should be capitalized. ACMG reserves the right to replace proprietary names with generic names to adhere to this policy.
Abbreviations • Use standard abbreviations. Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract.

Abstract Body, Tables, and Figures
• Abstracts submitted for the ACMG annual meeting are published online. It is the responsibility of the author to proofread the abstract carefully.
• You are allotted 4,200 characters (including spaces) for your abstract. The program will not allow submission if the maximum number is exceeded. If you cut and paste from a word document, use the Special Characters or Symbols menu to enter Greek letters, symbols, and for inserting HTML code such as bold, italic, super and subscripted symbols. Please note: scroll to the bottom of the special character’s menu to locate HTML code such as bold, italic, super and subscripted symbols.
• The abstract may be structured (i.e., abstracts divided into sections using terms such as Introduction, Methods, Results, Conclusions, etc.) or unstructured.
• Do not use bold type or underline formatting. Italic type is acceptable.
• Text may be in multiple paragraphs.
• Special Greek and mathematical symbols are available in a character map within the submission system.
• Use numerals to indicate numbers, except when beginning sentences.
• Simple tables and graphs may be included. The online abstract submission system provides step-by-step instructions on inserting tables and graphs in the preferred HTML format.
• Any references should be noted as citations within the text and not as footnotes at the end.